INTEK HAS DEVELOPED OVER 20 VERY PROMISING TUMOR-ASSOCIATED AND POSSIBLY TUMOR-SPECIFIC MURINE MONOCLONAL ANTIBODIES AGAINST SQUAMOUS CELL CARCINOMA (SCC) TUMORS.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1985
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
2987
Agency Tracking Number:
2987
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
1450 Rollins Road, Burlingame, CA, 94010
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RONALD JONES
PRINCIPAL INVESTIGATOR
(415) 340-0530
Business Contact:
() -
Research Institute:
n/a
Abstract
INTEK HAS DEVELOPED OVER 20 VERY PROMISING TUMOR-ASSOCIATED AND POSSIBLY TUMOR-SPECIFIC MURINE MONOCLONAL ANTIBODIES AGAINST SQUAMOUS CELL CARCINOMA (SCC) TUMORS. THERE ARE CURRENTLY NO IMMUNOLOGICAL METHODS IN USE FOR MONITORING SCC PATIENTS FOR RECURRENCE OF TUMOR, OR FOR IDENTIFICATION OF METASTASES. THE SPECIFICITY OF THESE ANTIBODIES FOR SCC TUMORS, BUT NOT FOR NORMAL TISSUES, IS GREAT ENOUGH TO WARRANT FURTHER EXAMINATION OF THEIR USEFULNESS IN A VARIETY OF DIAGNOSTIC AND THERAPEUTIC FORMATS. THE GOAL OF THIS PROPOSAL IS TO DEVELOP IMMUNOASSAYS UTILIZING THESE MONOCLONAL ANTIBODIES TO DETECT ANTIGENS FOUND SPECIFICALLY IN ASSOCIATION WITH SCC TUMORS OF THE HEAD AND NECK. THE ULTIMATE GOAL IS TO BE ABLE TO MEASURE THESE ANTIGENS IN THE SERUM OF SCC PATIENTS. SUCCESSFUL COMPLETION OF PHASE I INCLUDES 1.IDENTIFICATION OF AN ANTIGEN SOURCE FOR EACH MONOCLONAL ANTIBODY (EITHER SCC TUMOR CELL LINES, HETEROTRANSPLANTS OF SCC LINES INTO NUDE MICE, OR SPENT CULTURE SUPERNATANT); TO DATE, THE BEST CANDIDATES FOR TUMOR-SPECIFIC ANTIBODIES HAVE BEEN DERIVED FROM IMMUNIZATIONS WITH FRESH OR FROZEN SCC TUMORS,2.ISOLATION OF SUFFICIENT ANTIGEN, NOT NECESSARILY IN PURE FORM, IN ORDER TO SET UP SOLID PHASE INHIBITION FORMAT IMMUNOASSAYS, 3.DEVELOPMENT OF IMMUNOASSAY SYSTEMS, AND 4.PRELIMINARY MEASUREMENT OF ANTIGEN LEVELS IN SCC PATIENT AND NORMAL SERA. PHASE II WILL INVOLVE LARGE SCALE CLINICAL STUDY OF THE DIAGNOSTIC & PROGNOSTIC UTILITY OF SCC ANTIGEN IMMUNOASSAYS.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government